Drug Repurposing in Alzheimer's Disease: Emerging Therapeutic Strategies and Promising Candidates - PubMed
4 hours ago
- #Alzheimer's disease
- #drug repurposing
- #neurodegeneration
- Drug repurposing offers a promising approach to accelerate Alzheimer's disease (AD) therapy development by utilizing drugs with established safety profiles.
- AD's complex pathophysiology involves amyloid-β plaques, tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and oxidative stress, necessitating multi-target strategies.
- Existing approved therapies, such as cholinesterase inhibitors and NMDA antagonists, are primarily symptomatic, while newer anti-amyloid antibodies face efficacy, safety, and cost challenges.
- Repurposed candidates target various AD pathways, including antidiabetics (e.g., metformin, GLP-1 agonists), antihypertensives (e.g., candesartan), anti-inflammatories (e.g., NSAIDs, pioglitazone), and neuroprotective agents (e.g., minocycline, sildenafil).
- Mitochondrial dysfunction is emerging as a key early factor in AD, with mitochondria-targeted therapeutics like SS-31, Mdivi-1, MitoQ, DDQ, and SkQ1 considered promising disease-modifying options.
- Advancements in artificial intelligence, multi-omics, and precision medicine enhance drug repurposing strategies, potentially overcoming current limitations and improving clinical outcomes.